Comments
Loading...
Latest news for Gilead Sciences (NASDAQ:GILD) Stock
Gilead Sciences Stock (NASDAQ: GILD)
Categories: All
Thursday, November 21, 2024
Monday, November 18, 2024
Friday, November 15, 2024
- Shares of pharmaceutical and healthcare stock...
- Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
- Gilead's Livdelzi (Seladelpar) Shows Sustaine...
- Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
- Wolfe Research Initiates Coverage On Gilead S...
Thursday, November 14, 2024
Wednesday, November 13, 2024
Tuesday, November 12, 2024
Friday, November 08, 2024
Thursday, November 07, 2024
- Oppenheimer Maintains Outperform on Gilead Sc...
- HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
- Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
- BMO Capital Maintains Outperform on Gilead Sc...
- Baird Maintains Neutral on Gilead Sciences, R...
- JP Morgan Maintains Overweight on Gilead Scie...
- RBC Capital Maintains Sector Perform on Gilea...
- Goldman Sachs Maintains Neutral on Gilead Sci...
- Cantor Fitzgerald Maintains Neutral on Gilead...
- Wells Fargo Maintains Overweight on Gilead Sc...
- Barclays Maintains Equal-Weight on Gilead Sci...
- Gilead Sciences shares are trading higher aft...
- Piper Sandler Maintains Overweight on Gilead ...
- Gilead Sciences Announces Late-Breaking Clini...
- Needham Reiterates Hold on Gilead Sciences
Wednesday, November 06, 2024
Tuesday, November 05, 2024
Wednesday, October 30, 2024
Tuesday, October 29, 2024
Monday, October 21, 2024
- Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
- Robinhood To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Monday
- Peering Into Gilead Sciences's Recent Short Interest
- This JD.com Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
- Evaluating Gilead Sciences: Insights From 15 Financial Analysts
- Leerink Partners Upgrades Gilead Sciences to ...
- Reported Saturday, Gilead And Merck's Islatra...